Literature DB >> 23428458

Conversion to the COBAS AmpliPrep/COBAS TaqMan CMV Test for management of CMV disease in transplant recipients.

Bobbi S Pritt1, Jeffrey J Germer, Eric Gomez-Urena, Callie J Bishop, Jayawant N Mandrekar, Cole L Irish, Joseph D C Yao.   

Abstract

Testing of clinical plasma specimens by the COBAS AmpliPrep/COBAS TaqMan CMV Test (CAP/CTM CMV), COBAS AMPLICOR CMV MONITOR Test (CAM CMV), and a laboratory-developed assay using analyte-specific reagents (LC CMV) demonstrated substantial result bias for CAP/CTM CMV versus CAM CMV (r = 0.436) and CAP/CTM CMV versus LC CMV (r = 0.773).
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Year:  2013        PMID： 23428458     DOI： 10.1016/j.diagmicrobio.2013.01.014

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


  3 in total

1.  Monitoring of cytomegalovirus viral loads by two molecular assays in whole-blood and plasma samples from hematopoietic stem cell transplant recipients.

Authors:  N Esther Babady; Cindy Cheng; Evelyn Cumberbatch; Jeffrey Stiles; Genovefa Papanicolaou; Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2015-02-04       Impact factor: 5.948

2.  Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience.

Authors:  Linda A Selvey; Wai H Lim; Peter Boan; Ramyasuda Swaminathan; Claudia Slimings; Amy E Harrison; Aron Chakera
Journal:  BMC Infect Dis       Date:  2017-07-17       Impact factor: 3.090

3.  Molecular and Culture-Based Bronchoalveolar Lavage Fluid Testing for the Diagnosis of Cytomegalovirus Pneumonitis.

Authors:  Susanna K Tan; Elizabeth B Burgener; Jesse J Waggoner; Kiran Gajurel; Sarah Gonzalez; Sharon F Chen; Benjamin A Pinsky
Journal:  Open Forum Infect Dis       Date:  2016-02-10       Impact factor: 3.835
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.